Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leisha A Emens

Showing results (71-80 of 114) with videos related to

Pageof 12
Sort By:
Frontiers in Physiology|November 16, 2020
Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast CancerHaoyang Mi, Chang Gong, Jeremias Sulam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanismElizabeth A Manning, John G M Ullman, James M Leatherman, et al.
Cancer Immunology Research|May 10, 2017
A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized MiceJeremy B Foote, Marleen Kok, James M Leatherman, et al.
Clinical Breast Cancer|June 22, 2021
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib StudyErika P Hamilton, Virginia Kaklamani, Carla Falkson, et al.
Human Pathology|November 4, 2015
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomasAshley Cimino-Mathews, Elizabeth Thompson, Janis M Taube, et al.
JAMA Ophthalmology|November 2, 2018
Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal VenulitisLeisha A Emens, S Lindsey Davis, Scott C N Oliver, et al.
The Journal of Experimental Medicine|May 11, 2005
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune responseAnne M Ercolini, Brian H Ladle, Elizabeth A Manning, et al.
Journal for Immunotherapy of Cancer|June 20, 2024
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic visionLeisha A Emens, Pedro J Romero, Ana Carrizosa Anderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 6, 2006
OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigenSatoshi Murata, Brian H Ladle, Peter S Kim, et al.
The Journal of Clinical Investigation|April 10, 2008
Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCsPeter S Kim, Todd D Armstrong, Hong Song, et al.
Pageof 12

Showing results (71-80 of 114) with videos related to

Sort By:
Pageof 12
Frontiers in Physiology|November 16, 2020
Digital Pathology Analysis Quantifies Spatial Heterogeneity of CD3, CD4, CD8, CD20, and FoxP3 Immune Markers in Triple-Negative Breast CancerHaoyang Mi, Chang Gong, Jeremias Sulam, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 4, 2007
A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanismElizabeth A Manning, John G M Ullman, James M Leatherman, et al.
Cancer Immunology Research|May 10, 2017
A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized MiceJeremy B Foote, Marleen Kok, James M Leatherman, et al.
Clinical Breast Cancer|June 22, 2021
Impact of Anti-HER2 Treatments Combined With Atezolizumab on the Tumor Immune Microenvironment in Early or Metastatic Breast Cancer: Results From a Phase Ib StudyErika P Hamilton, Virginia Kaklamani, Carla Falkson, et al.
Human Pathology|November 4, 2015
PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomasAshley Cimino-Mathews, Elizabeth Thompson, Janis M Taube, et al.
JAMA Ophthalmology|November 2, 2018
Association of Cancer Immunotherapy With Acute Macular Neuroretinopathy and Diffuse Retinal VenulitisLeisha A Emens, S Lindsey Davis, Scott C N Oliver, et al.
The Journal of Experimental Medicine|May 11, 2005
Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune responseAnne M Ercolini, Brian H Ladle, Elizabeth A Manning, et al.
Journal for Immunotherapy of Cancer|June 20, 2024
Challenges and opportunities in cancer immunotherapy: a Society for Immunotherapy of Cancer (SITC) strategic visionLeisha A Emens, Pedro J Romero, Ana Carrizosa Anderson, et al.
Journal of Immunology (Baltimore, Md. : 1950)|January 6, 2006
OX40 costimulation synergizes with GM-CSF whole-cell vaccination to overcome established CD8+ T cell tolerance to an endogenous tumor antigenSatoshi Murata, Brian H Ladle, Peter S Kim, et al.
The Journal of Clinical Investigation|April 10, 2008
Antibody association with HER-2/neu-targeted vaccine enhances CD8 T cell responses in mice through Fc-mediated activation of DCsPeter S Kim, Todd D Armstrong, Hong Song, et al.
Pageof 12